Sage Therapeutics, Inc. (SAGE)
| Market Cap | 4.96B |
| Revenue (ttm) | 1.11B |
| Net Income (ttm) | 606.07M |
| Shares Out | 51.98M |
| EPS (ttm) | 11.43 |
| PE Ratio | 7.44 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $85.00 |
| Previous Close | $83.45 |
| Change ($) | 1.55 |
| Change (%) | 1.86% |
| Day's Open | 81.73 |
| Day's Range | 80.47 - 85.10 |
| Day's Volume | 1,067,471 |
| 52-Week Range | 25.01 - 98.38 |
American BriVision: Deep Dive Into Market Potential
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform t...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform t...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the liv...
Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.
Biogen recently announced a $1.5 billion collaboration agreement with Sage Therapeutics. Despite an earlier failed trial, Zuranolone is a promising therapy for depression.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform th...
The shares of Sage Therapeutics Inc (NASDAQ:SAGE) are down 1.8% at $72.78 at last check, after Raymond James downgraded the stock to "Market Perform" from "Outperform," following its recent $1...
Biogen (BIIB) and Sage Therapeutics (SAGE) collaborate to develop latter's zuranolone for depression indications and SAGE-324 for essential tremor.
Biogen Inc. and Sage Therapeutics Inc. said Monday they have agreed to jointly develop therapies to treat depression and movement disorders in a deal in which Biogen will give Sage $1.525 bill...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license ag...
Sage Therapeutics' (SAGE) Management on Q3 2020 Results - Earnings Call Transcript
Shares of Sage Therapeutics (NASDAQ: SAGE) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share increased 41.67% year over year to ($2.03), which beat the...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to tran...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform t...
Sage Therapeutics has shown impressive results on the charts YTD, where shareholders have enjoyed +169% gains since the selloff. The stock has bounced away from support nicely 5 times since th...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to tran...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform t...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform t...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform t...
Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
With depression rates up amid the economic and health crises, mental health should be treated like a physical illness, Sage Therapeutics CEO Jeff Jonas said on "Mad Money."
Sage Therapeutics CEO: Mental health is integral to returning to work
"We need to treat mental health like a physical illness, treat it urgently, in order to get people back to work and back to their families," Sage Therapeutics CEO Jeff Jonas said.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc.
Sage Therapeutics, Inc. (SAGE) CEO Jeffrey Jonas on Q2 2020 Results - Earnings Call Transcript
Shares of Sage Therapeutics (NASDAQ:SAGE) were flat in pre-market trading after the company reported Q2 results.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc.
With its recent clinical trial stumble and falling revenues for its only approved drug on the market, Sage may be in trouble.
If you’re looking to hedge some downside, or if you think the market has gone too far to the upside, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identif...
The 2020 year is practically halfway done, and this has really been the year of the biotech.
The company, which failed pivotal clinical trials investigating major depression, aims to reverse its fortunes this year.
SAGE Therapeutics, Inc. (SAGE) CEO Jeffrey Jonas on Q1 2020 Results - Earnings Call Transcript
Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.
As of late, it has definitely been a great time to be an investor in Sage Therapeutics.
Sage Therapeutics (SAGE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Shares of Sage Therapeutics Inc. were down 0.6% in premarket trading on Wednesday after it announced a restructuring plan that includes letting go of 340 employees, which is more than half of ...
Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Sage Therapeutics (SAGE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Sage Crumbled After Single Trial Failure, But Few Catalysts In The Near Term May Turn Things Around
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2019 Results Conference Call February 27, 2020 8:00 AM ET
A revenue miss and a lack of news on its depression drug candidate had shareholders down in the dumps.
Sage Therapeutics (SAGE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
An important drug candidate failed to meet its primary endpoint in a clinical trial. That left the door open for a new competitor.
Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering.
Insider buying can be an encouraging signal for potential investors. Two energy companies saw insiders return to add to their stakes last week.
Sage Therapeutics (SAGE) shares rose more than 7% in the last trading session, amid huge volumes.
About SAGE
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that i... [Read more...]
| Industry Biotechnology | IPO Date Jul 18, 2014 |
| CEO Jeffrey Jonas | Employees 298 |
| Stock Exchange NASDAQ | Ticker Symbol SAGE |
Analyst Forecasts
According to 22 analysts, the average rating for SAGE stock is "Buy." The 12-month stock price forecast is 102.00, which is an increase of 20.00% from the latest price.